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Abstract: The present study was undertaken to investigate the immunohistochemical expression of pulmonary surfactant proteins (SPA, SP-B, proSP-C) associated with proliferating cell nuclear antigen (PCNA), thyroid transcription factor-I (TTF-I), and lymphocytic
phenotypes (CD3+ T and CD79αcy+ B cells) in ovine lungs with exudative and verminous pneumonia. Pneumonic lungs (n = 50) were
classified as presenting fibrinous bronchopneumonia (n = 16), abscessing necrotic bronchopneumonia (n = 10), verminous pneumonia
(n = 15), and interstitial pneumonia (n = 9). The lungs with fibrinous bronchopneumonia displayed consolidation of lobes with adhesion
to surrounding tissues. The lungs with verminous pneumonia were characterized by lungworm sections in airways. Type II pneumocytes
were highly proliferated in the pneumonic lungs and revealed intense immune positivity for the surfactant proteins. Proliferated type II
cells, lymphocytes, and fibroblasts showed a strong immune reaction for PCNA. TTF-I positivity occurred in the ovoid nuclei of alveolar
II epithelial cells. Lymphoid infiltrations revealed a positive reaction to the CD markers. In conclusion, the present study revealed that
alveolar type II epithelial cells were severely proliferated in the sheep lungs with pneumonia and produced most of surfactant proteins
compared to normal type II cells. Consequently, type II cells are very important in the restoration of damaged lungs, and surfactant
apoproteins might play an important role in the host defense mechanisms against involved microorganisms.
Key words: Immunohistochemistry, pneumonic ovine lungs, surfactant proteins

1. Introduction
Pneumonia is an important lung disease arising from
the protective inflammatory response of the airways and
alveoli in the lungs to injury and infection, resulting in
the damaging of parenchymal tissue (1). The disease
causes heavy economic problems in ovine farms, due
to either mortality or decreased growth, along with
animal welfare implications. Pneumonia occurs in
different types in sheep, one of which is acute fibrinous
bronchopneumonia observed in sheep, and the other
is the chronic nonprogressive pneumonia of lambs (2).
The alveoli of the lungs are mainly covered by two types
of alveolar epithelium named type I and II cells. Type I
alveolar epithelial cells constitute approximately 96%
of the alveolar surface and allow the exchange of gases
between the alveoli and the vascular compartment. Type
II cells play an important role in the repair of damaged
parenchyma and in preventing the collapse of alveoli
(3–6). Lung surfactants are surface-active substances
produced by alveolar type II epithelial cells and nonciliated
Clara cells. The main function of surfactant proteins is to
reduce the surface tension at the air–liquid interface in
the alveoli of the lungs. Pulmonary surfactant apoproteins
are a mixture of lipids and proteins. To date, four types of
* Correspondence: enverbeytut@hotmail.com
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surfactant apoproteins have been identified and named as
SP-A, SP-B, SP-C, and SP-D regarding the chronological
order of their detection (5,7–11).
Proliferating cell nuclear antigen (PCNA) is a wellcharacterized antigen produced in the nuclei of cells
during DNA replication, and it has a central role in many
cellular processes including DNA synthesis and damage
repair. PCNA has often been used as a diagnostic and
prognostic tool in different types of neoplasms (12).
Thyroid transcription factor-I (TTF-I) is also found
mainly in normal type II alveolar epithelial cells in the
lungs and has important roles in epithelial morphogenesis
and synthesis of pulmonary surfactant proteins and in the
regulation of secretory products in Clara cells. Since TTF1 usually retains its tissue specificity, it has often been used
in the identification of primary tumor cell lines in some
thyroid and lung carcinomas (13).
Pulmonary surfactants have mainly been examined
in neoplastic human (14,15) and ovine (16–18) lungs.
However, there is no record of the observation of
immunohistochemical expression of surfactant proteins
(with the exception of SP-D) in ovine lungs with exudative
and verminous pneumonia. The present study was
undertaken to investigate the immunohistochemical
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expression of surfactant apoproteins (SP-A, SP-B,
proSP-C) associated with PCNA and TTF-I. Additionally,
the lymphocyte infiltration into the pneumonic lungs was
evaluated by determination of lymphocytic phenotypes
(CD3+ T and CD79αcy+ B cells).
2. Materials and methods
2.1. Tissues and histopathology
Materials of the study were the lungs from sheep of
various ages with pneumonia (n = 50) and healthy sheep
(n = 5) slaughtered at a local abattoir. Following the gross
examination, all lung specimens were fixed in 10% neutral
buffered formalin solution, routinely processed, and
embedded in paraffin. Sections of 4 µm in thickness were
cut and stained with hematoxylin and eosin (H&E).
2.2. Immunohistochemistry
Serial lung sections were stained immunohistochemically
using antiserum against pulmonary surfactant apoproteins
(SP-A, SP-B, proSP-C), PCNA, TTF-I, and CD3+ T and
CD79αcy+ B lymphocytes (19). Details of the primary
antibodies used in the study are shown in the Table.
Sections of 4 µm in thickness were deparaffinized in
xylene and rehydrated through graded alcohols to water.
Endogenous peroxidase activity was blocked with 3%
hydrogen peroxide in methanol for 20 min. The sections
were incubated with Tris-buffered saline (TBS, pH 7.6) for
5 min and subsequently placed in citrate-buffered saline
(pH 6.0) in a microwave oven for 20 min for antigen
retrieval. After having been washed with TBS for 5 min,
the sections were incubated with 5% normal goat (SPA, SPB, proSP-C, TTF-I) or rabbit (PCNA, CD79αcy) serum for
1 h at room temperature. The sections were then incubated
with the primary antibodies. Having been washed with
TBS three times for 5 min, respectively, the sections were
incubated with biotinylated goat antirabbit IgG (SP-A,
SP-B, proSP-C, TTF-I) and biotinylated rabbit antimouse
IgG (PCNA, CD79αcy), at a dilution of 1/200 in TBS,
for 60 min at room temperature (secondary antibodies

supplied by Dako, Carpinteria, CA, USA). After further
washing of the sections with TBS, they were treated with
streptavidin peroxidase complex (Dako), at a dilution of
1/300, for 30 min at room temperature. Polyclonal rabbit
antihuman CD3 antibody and the LSAB2 system (Dako)
were used to differentiate T lymphocytes, following
the manufacturer’s instructions. Immunoreaction was
obtained using 3,3-diaminobenzidine or 3-amino-9ethylcarbazole as the chromogen. Mayer’s hematoxylin
was used to counterstain. All primary antibodies were
removed from negative control sections, which were
incubated with either TBS or diluted normal serum from
the species in which the primary antibodies were raised.
Mean numbers of immunopositive cells that exhibited
specific immunolabeling for each antibody were assessed
in three most representative fields with the 40× objective
of a light microscope.
3. Results
3.1. Gross and histopathological findings
Pneumonic lungs revealed varying degrees of consolidation,
fibrin collections, and adhesions in the ventral or dorsal
parts of lung lobes. Based on histopathology, pneumonia
was classified as fibrinous bronchopneumonia (n =
16), abscessing necrotic bronchopneumonia (n = 10),
verminous bronchopneumonia (n = 15), or interstitial
pneumonia (n = 9). The predominance of fibrinous
bronchopneumonia was the presence of a mixture of
macrophages and neutrophils with the accumulation of
oat cells. There was also edema in alveoli, congestion, and
hemorrhages as well as fibrin clots within the interlobular
septa. Abscessing necrotic bronchopneumonia showed
varying sizes of necrotic foci surrounded by connective
tissue, neutrophilic accumulation within the airways,
and, peripherally, gland-like type II cell proliferation.
Verminous pneumonia revealed adult worm sections
and eggs within airways with eosinophilic leukocytic
infiltration. There were also large subpleural lymphoid foci

Table. Details of primary antibodies used for IHC.
Antibody

Dilution

Incubation conditions

Source (catalogue or clone number)

Polyclonal rabbit antibovine SP-A*

1/1000

Overnight, 4 °C

Chemicon (AB3424)

Polyclonal rabbit antisheep SP-B*

1/2000

Overnight, 4 °C

Chemicon (AB3780)

Polyclonal rabbit antihuman proSP-C*

1/500

Overnight, 4 °C

Seven Hills Bioreagents (WRAB-SPC)

Polyclonal rabbit antirat TTF-1*

1/1000

Overnight, 4 °C

Seven Hills Bioreagents (WRAB-TTF I)

Monoclonal mouse antirat PCNA*

1/2000

Overnight, 4 °C

Chemicon (PC10)

Polyclonal rabbit antihuman CD3*

1/150

Room temperature

Monoclonal mouse antihuman CD79αcy*

1/25

Overnight, 4 °C

Dako (N1580)
Dako (M7051)

*Antibody has been shown to cross-react with sheep according to the manufacturer’s datasheet.
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with germinal centers containing mineralized material
and neutrophilic exudation in airways. The mineralized
material was identified as a remnant of dead parasites
by using H&E-stained sections. Interstitial pneumonia
was characterized by interalveolar septal thickening with
proliferated type II cells and mononuclear cell infiltration.
Healthy lungs did not show any lesions.
3.2. Immunohistochemistry
3.2.1. Surfactant proteins (SP-A, SP-B, proSP-C)
In fibrinous bronchopneumonia, type II cells proliferated,
glandular in appearance, around the necrotic areas and
showed positive labeling for SP-A (Figure 1) and SP-B. The
number of immunopositive type II cells for the markers
at three most representative areas varied between 70 and
100 cells. SP-A immunolabeled hyperplastic type II cells
were recognized by the presence of numerous cuboidal
nuclei, which formed a continuous alveolar lining, or
gland-like proliferations around the necrotic foci and
neutrophilic collections. Extracellular staining was seen to
be high in SP-A-immunostained sections compared to SPB. In less affected lungs, the number of proliferated type
II cells was lower than seen in chronically affected sheep.
Alveolar macrophages also showed a positive cytoplasmic
reaction to both SP-A and SP-B. In cases of acute
bronchopneumonia showing septal hyperemia, fibrinous
exudation, and edema in the lung parenchyma, alveolar
type II cell hyperplasia was found only in alveoli and the
rate of the cells was 30–40. Type II cells reacting to the
SP-A and SP-B antibodies were easily distinguished from
the oat cells, which did not show a positive labeling for
SPs. Proliferated type II cells infrequently revealed mitosis
in that cytoplasmic granules were also positive for SP-A
and SP-B. In a few lungs with typical signs of pneumonic
pasteurellosis, the mean number of type II cells was 40–50.
However, in alveoli densely occluded by oat cells, type II
cells were not seen, or only a few cells were scarcely found.

In hyperplastic type II cells, positive reaction for SP-B
was evidently detected in the large cytoplasmic granules
of complete cytoplasm, which were most probably
lamellar bodies and caused expansion of the cytoplasm
and hypertrophy of the cells. In normal lungs, positive
staining occurred only at the apical cytoplasm of the cells.
Nonciliated Clara cells positively stained with both SP-A
and SP-B were noticeably frequent in terminal bronchioles
compared to healthy lungs (Figure 2). ProSP-C labeling
was detected in the perinuclear area of the alveolar type
II epithelial cells. No extracellular reaction was detected
in any cases. SP-C positive staining openly disclosed type
II cells without positive reaction of Clara cells. In healthy
or unaffected areas of pneumonic lungs, type II cells were
mainly found at alveolar septa and within alveoli, which
were found to protrude into the lumen. As in SP-B stained
sections, proliferated type II cells showed cytoplasmic
distension and intense reaction for proSP-C.
In abscessing necrotic bronchopneumonia, SP-A
and SP-B stainings confirmed that numerous type II
cells proliferated at the margin of the fibrotic capsule
surrounding the necrotic areas (Figure 3). The number
of alveolar type II cells was over 100 in the high-power
field (HPF). Although type II cells were difficult to
identify among inflammatory cells and fibrocytes in H&Estained sections, immunolabeling openly disclosed the
hyperplastic type II cells in all parts of the lungs. Immune
reaction products were large granules distributed within
the cytoplasm of the cells. In some areas, hyperplasia
of type II cells was so severe that all microscopic fields
consisted of the cells. However, in some areas where the
fibroblastic reaction was predominant, the number of
type II cells was fewer than in other regions. As expected,
immunostainings using proSP-C identified numerous
proliferated type II cells (Figure 4). Type II cells were rarely
desquamated into the alveoli and mixed with alveolar

Figure 1. SP-A immunopositive reaction in the cytoplasm
of proliferated type II cells in a lung with fibrinous
bronchopneumonia. IHC. Bar: 51 µm.

Figure 2. SP-A positive labeled nonciliated Clara cells in terminal
bronchioles. IHC. Bar: 51 µm.
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Figure 3. Diffuse SP-B immunopositive reaction in the
cytoplasm of type II pneumocytes in a lung with purulent
bronchopneumonia. IHC. Bar: 166 µm.

Figure 4. ProSP-C immunopositive reaction in the perinuclear
area of proliferated type II cells in alveoli having edema fluid.
IHC. Bar: 51 µm.

macrophages. However, macrophages did not show a
positive reaction for the marker. Clara cells did not show a
positive immunolabeling to proSP-C.
In verminous pneumonia, where lungs contained
worms or eggs in airways, proliferation of type II
pneumocytes was generally moderate (Figure 5).
Immunolabeled cells for SP-A and SP-B were often seen
to desquamate into the alveolar lumen and mixed with
worms and infiltrative cells. Severe hyperplasia of type
II cells immunopositive to SP-A and SP-B were evident
around the parasitic foci, although a few type II cells were
detected in the alveoli and interalveolar septum. In some
areas with thickened alveolar septa, the number of type II
pneumocytes and surfactant protein expression increased
parallelly to the thickening of the septum. Even though
alveoli around the inflammatory foci could not be easily
observed because of severe fibrosis and inflammatory
cells, high amounts of extracellular surfactant protein
for SP markers and glandular hyperplasia of type II

pneumocytes were detected. In particularly, surfactant
protein expression at inflammatory foci was seen as focal
aggregations of large brownish granules, or rarely within
the cytoplasm of type II cells. Moreover, in some areas
type II cells were difficult to identify because of severe
extracellular surfactant protein reaction to the marker.
In
interstitial
pneumonia,
immune-stained
sections revealed that thickening of the alveolar septa
was predominantly due to the hyperplasia of type II
pneumocytes. Intense reactivity to both SP-A and SP-B was
present in both extracellular surfaces and the cytoplasm of
type II cells. In some areas that contained few neutrophils
and thickened alveolar septa, type II cells highly proliferated
and secreted high amounts of surfactant. The mean number
of proliferated type II cells in these areas was over 100 cells
in the HPF. Unlike exudative pneumonia, type II cells did
not show a glandular pattern of hyperplasia and randomly
proliferated in the parenchyma. Interestingly, even though
the cells were highly proliferated, extracellular expression
of SP-A or SP-B was rarely noticed. ProSP-C positive
staining confirmed that type II cells were mixed with
inflammatory cells and fibrocytes at the thickened alveolar
septa. ProSP-C positive cells were also seen to increase in
the margin of interlobular septa and large airways.
Healthy lungs revealed a small number of
immunopositive type II cells to the SPs, with 2 or 3 cells in
the HPF (Figure 6). Positive cells were commonly located
at the corners of alveoli. Immunoreaction products were
mainly seen to be small granules. The granules in the
sections stained with SP-A and SP-B were located at the
apical surface of the cells, but in proSP-C-stained sections,
immunoreaction products were seen next to the nuclei.
At high magnification (100× objective), the number of
granules was smaller than that seen in the pneumonic
lungs. Nonciliated Clara cells of terminal bronchioles were
immunopositive against SP-A and SP-B.

Figure 5. Positive labeling for SP-B in the cytoplasm of a few type
II cells along with parasite eggs in the lung. IHC. Bar: 166 µm.
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Figure 6. Immunopositive reaction of type II cells for SP-B in a
healthy sheep lung. IHC. Bar: 51 µm.

3.2.2. Proliferating cell nuclear antigen
PCNA nuclear positive reaction was predominantly
detected in ovoid nuclei of type II cells that proliferated
in a glandular appearance at the margin of fibrotic
tissue surrounding necroses (Figure 7). The number of
immunopositive cells varied among the pneumonic lungs
and a high number of the cells were seen in lungs, resulting
in fibrosis. In fibrinous and necrotic bronchopneumonia,
nuclear positive cells were mainly found at the margin
of necrotic areas, with over 100 cells in the HPF. PCNA
positive immunolabeling was also found in the germinal
centers of bronchus-associated lymphoid tissue (BALT)
and at the epithelial lining of bronchi and bronchioles.
In healthy lungs, few cells showed a positive reaction
in alveolar septa, with 3–5 cells in the HPF. In terminal
bronchioles, few lining epithelial cells showed nuclear
positivity to PCNA. However, these cells could not
be identified as either Clara or ciliated epithelial cells.
PCNA positive stained spindle cells were identified as a

Figure 7. Widespread positive reaction for PCNA of proliferated
type II cells around the necrotic foci in a pneumonic lung. IHC.
Bar: 543 µm.
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fibroblastic lineage, which was confirmed in H&E-stained
sections. Additionally, a few cells showing mitosis at the
alveolar septa revealed positivity to PCNA.
3.2.3. Thyroid transcription factor-I
TTF-I positive reactions predominantly occurred in the
ovoid nuclei of type II cells. Nonciliated and ciliated lining
cells of terminal bronchioles from both affected and healthy
lungs revealed nuclear expression for TTF-1, with a strong
immunolabeling of type II cells in the lungs of young
animals. Even though TTF-I positive reaction was found
in all alveolar type II cells, a diffuse and strong reaction
for the marker was detected in the nuclei of proliferated
epithelial cells at the margin of fibrotic tissue in lungs
with abscessing necrotic bronchopneumonia. Healthy and
unaffected areas of the pneumonic lungs expressed nuclear
reaction to TTF-1.
3.2.4. Lymphocytic phenotyping (CD3+ T and CD79αcy+
B cells)
The number of CD3+ T cells in all of the pneumonic
lungs was higher than the number of CD79αcy+ B cells. In
verminous bronchopneumonia, CD3+ T and CD79αcy+ B
cells were mainly seen in lymphocytic cuffing of airways.
Abscessing necrotic bronchopneumonia often displayed
positively stained lymphocytes for the CD markers in the
pneumonic parenchyma. CD3+ T cells often infiltrated into
the thickened alveolar septa by fibrosis and the number
of infiltrated CD3+ T cells increased in the lungs showing
lymphoid cuffing of airways. CD3+ T and CD79αcy+ B cell
infiltrations were also seen in subpleural lymphoid foci
containing central calcified masses and in mononuclear
infiltrations of vessels. Although CD3+ T and CD79αcy+
B cells infiltrated into the peribronchial areas and alveolar
septa, a high number of the cells was detected in the
peribronchial lymphoid tissues (Figure 8). No positive
cells for the CD markers were found in healthy lungs.
4. Discussion
Pneumonia is an important cause of loss in the sheep
industry and many forms of the disease have been reported
with clinical signs and mortality (1). The disease begins
with a severe inflammatory response in the wall of alveoli
and subsequent parenchymal destruction and extensive
fibrohyperplasia of the alveolar airspace ensues, consisting
of fibroblasts, capillaries, and connective tissue products
(1,20). In the present research pneumonic lungs revealed
marked fibrosis, alveolar epithelization, and mononuclear
cell infiltration around the airways. In particularly, in lungs
with fibrinous bronchopneumonia, alveoli and bronchioles
were occluded by fibrinous exudation and were repaired
by connective tissue. However, proliferative or reparative
characteristics of alveolar type II cells in pneumonic
lungs have not been investigated to date. Moreover, little
information is available regarding the repair of damaged
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Figure 8. Numerous CD3+ T (A) and a few CD79αcy+ B (B) lymphocytes in a lung
chronically affected by pneumonia. IHC. Bar: 51 µm.

parenchyma caused by different infectious agents and
worms in ovine lungs with pneumonia. Therefore, this
research was undertaken to investigate the proliferation
of type II cells in various types of ovine pneumonia by
using surfactant proteins as a marker for type II cells
and it was found that type II cells proliferated highly in
pneumonic lungs regardless of the injurious agent. Grubor
et al. (21) found that hyperplasia of alveolar type II cells
was the most striking histological finding in Mannheimia
haemolytica-infected lambs and that cell-associated SP-D
expression decreased with the progression of inflammation
and with the increased presence of proliferative alveolar
epithelium. Alveolar injury begins with damage or
desquamation of type I epithelium, followed by type II
cell hyperplasia and eventually transformation of type II
cells into type I epithelium. Thus, type II cell hyperplasia
represents a nonspecific reparative response to various
forms of lung injury and plays important roles in lung
development and restoration of the lung parenchyma (22).
In this work, identification of type II cells depended on
the presence of cuboidal nuclei and cytoplasmic granules
supposed to be osmophilic lamellar bodies in the SPimmunostained sections, as reported by others (3,6).
Hyperplasia of alveolar type II epithelial cells was higher
in cases of pneumonia caused by bacterial agents than
those of verminous pneumonia. Therefore, it is reasonable
that hyperplastic type II cells developed as a response
to alveolar injury in a variety of pulmonary disorders,
especially in the setting of inflammation and interstitial
fibrosis and during the healing phase of parenchymal
injury. Shilo et al. (23) reported that type II cell hyperplasia
is most evident in severe alveolar damage, but it is also

detectable in organizing or interstitial pneumonia. It is
also well known that type II cells serve as stem cells for
the replacement of type I cells that are damaged as a
consequence of pulmonary diseases or chemical-induced
injury (3). Likewise, type I cells appear to be incapable of
dividing and, moreover, these cells are quite sensitive to
injurious agents (3). Our study also found that type II cell
hyperplasia was invariably higher in chronically affected
lungs compared to those of acute stage.
The present study found that SP-A positive reaction
was generally extracellular within the alveoli or in the
cytoplasm of type II cells from healthy lungs and those with
pneumonia. However, extracellular SP-A immunopositive
reaction was stronger in pneumonic lungs compared to
healthy lungs. Release of most SP-A into the alveoli by
constitutive secretion, independently of lamellar bodies,
might explain the strong extracellular positivity for SP-A
in pneumonic lungs, as stated by others (5,9,24). In
accordance with our results, it was reported that SP-A
content in inflamed lungs was higher than that seen in
healthy lungs (5) and that lamellar bodies of type II cells
contain small amounts of SP-A (6,25). It was also reported
that most of the SP-A expressed into the alveolar surface
is again taken up by the alveolar type II epithelial cells,
catabolized, and transported into osmophilic lamellar
bodies for recycling of the protein (26). Thus, cytoplasmic
SP-A immunolabeling of the alveolar type II cells is most
probably due to the redirection of captured SP-A to the
lamellar bodies. SP-A immunopositive reaction was also
found in the cytoplasm of some alveolar macrophages,
in accordance with the results reported by Balis et al.
(22). Aggregation of SP-A may lead to the activation
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of macrophages and the stimulation of phagocytosis.
Likewise, SP-A in humans has been reported to induce
macrophage and neutrophil uptake and the killing of
pathogens in the lungs (24). Many alveolar type II cells
showed twin nuclei with a single cytoplasm and they
protruded into the alveolar lumen, which was confirmed
by PCNA staining. SP-A immunopositive twin cells
demonstrated propagation capacity and mitotic activity
of the cells. Additionally, SP-A positivity was detected in
the Clara cells of terminal bronchioles. SP-A is the most
abundant and best-characterized protein of the pulmonary
surfactants produced by Clara cells (5,7,24,27).
It was reported that mature SP-B is found exclusively
in the osmophilic lamellar bodies of the alveolar type
II cells, where it is stored and expressed into the alveolar
lumen to form tubular myelin (5,8). In this research,
mature SP-B immunopositive reaction occurred especially
in the apical surface area of the proliferated type II cells,
and immunoreaction products appeared as fine granules,
as shown by others (11,28). Although some authors
(10,25,27) reported that SP-A is the major protein of
the surfactant system, lamellar bodies particularly
contain SP-B and SP-C. This supports our results, with
more strong immunopositivity of lamellar bodies in the
cytoplasm of type II cells for SP-B than that seen for SPA. Immunolabeling for SP-B in the hyperplastic type II
cells was evidently stronger than that seen in normal type
II cells, consistent with the results reported by Balis et al.
(22). Strong immunostaining of hyperplastic type II cells in
the areas resulting in fibrosis facilitated their identification
among the inflammatory infiltrates. The apical cytoplasm
of the proliferated type II cells was seen to expand because
of the multiple lamellar bodies positively labeled for mature
SP-B. The strong immunoreactivity for SP-B and enhanced
cytoplasmic rate of the proliferated type II cells were most
probably due to the storage of the protein in lamellar bodies
before secretion into the alveolar lumen. Similar to our
results, Miller and Hook (3) reported that hypertrophy of
type II cells is caused by an increase in the number or size
of cytoplasmic lamellar bodies. SP-B positive staining was
also observed in the cytoplasm of Clara cells of the terminal
bronchioles. Like type II cells, Clara cells constitute a
major hyperplastic population and progenitors of ciliated
epithelium following bronchial injury (21).
SP-C is restricted to only type II cells (28,29) and
therefore has commonly been used in the identification of
tumors caused by this cell lineage in sheep lungs (16–18).
In the present report, strong immunolabeling of proSP-C
was noted in hyperplastic type II cells of pneumonic lungs.
While SP-A and SP-B immunopositivity indicated only
alveolar type II cells and Clara cells, proSP-C positive
reaction confirmed both hyperplastic and normal type
II cells in fibrotic bundles and in alveoli of pneumonic

62

and healthy lungs. Like SP-A and SP-B, proSP-C
immunopositive type II cells were predominantly detected
around the necrotic foci and neutrophil collections,
along with the strong reaction of cells in glandular
shapes at the margin of the fibrotic capsule. These results
confirmed the hyperplastic and restorative capacity of
type II pneumocytes in damaged lung tissue caused by
injurious agents. Although immunoreaction products to
SP-A and SP-B markers were seen predominantly in the
apical surface of type II cells, SP-C immunopositivity was
detected in the perinuclear areas of the cells. However,
Clara cells did not show SP-C positive reaction, as reported
earlier (16–18,29).
Immunolabeling to PCNA has often been used to
elucidate the prognosis of various neoplasms in human
(12) and sheep (17) lungs. PCNA immunolabeling in the
present work was used to demonstrate the proliferative
capacity of type II epithelial cells in pneumonic lungs.
Nuclear positive reaction to PCNA was predominantly
detected in the proliferated cells in glandular shapes
at the margins of the fibrotic capsules surrounding
the necrotic areas. The number of positive cells varied
among the pneumonic lungs, with high numbers of
PCNA immunopositive cells in lungs resulting in fibrosis.
Immunopositive cells having round or ovoid nuclei
around the necrotic areas were most likely proliferative
type II cells. Likewise, strong expression of surfactant
proteins in the same areas confirms type II cells. A PCNApositive reaction was also present at the BALT, confirming
the mitotic capacity of the cells. Additionally, PCNA
positive cells having thin nuclei around the necrotic areas
were also consistent with morphological characteristics of
fibroblasts, indicating fibrotic repair of the damaged lungs.
It has been shown that TTF-I is a useful marker in
the diagnosis of thyroid and lung tumors (13). Alveolar
epithelial cells of pneumonic and healthy lungs revealed
diffuse nuclear labeling for TTF-I. Regardless of the
type and stage of pneumonia, TTF-I expression was
intense in type II cells showing gland-like proliferations.
Consequently, the marker might be considered as a useful
tool in the identification of lung epithelium, as neoplastic
cells. However, lining epithelial cells of airways, except for
nonciliated Clara cells, did not show a positive reaction for
TTF-I.
Lymphocytic aggregations in the peribronchial
and peribronchiolar tissues were constantly present in
chronically affected pneumonic lungs, associated with
fibrosis. Lymphocytic aggregations were clearly seen to
increase around the airways and alveolar septum in lungs
with verminous and exudative pneumonia compared
to healthy lungs. In these spaces, the number of CD3+ T
cells was predominantly high compared to CD79αcy+ B
cells, as reported by Oros et al. (30). Such lymphocytic
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proliferations may indicate a cell-mediated nonspecific
immune response in ovine lungs with pneumonia.
Although this work confirmed the predominance of CD3+
T cells in peribronchial and peribronchiolar lymphocyte
proliferations, T cell subpopulations need to be determined
in ovine pneumonia.
In conclusion, the present study revealed that type
II cells are the main cells proliferating in lungs with
inflammation and that the cells have very important roles
in the reparative process. This research also found that

necrotic parenchyma is replaced by fibrous tissue instead
of regeneration. This research clearly revealed that in
lungs with verminous pneumonia type II cell hyperplasia
was less prominent as compared to exudative pneumonia.
This result might show that lung parasites did not incite
an inflammatory reaction in the absence of secondary
infection in ovine lungs. It might be said also that
increased secretion of the surfactant proteins with type II
cell hyperplasia is not only for restoration of the damaged
lungs but also might be for the killing of microbial agents.
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